HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
HA-1A is a human monoclonal IgM antibody that binds to endotoxin. The results of the clinical trials of HA-1A demonstrate that HA-1A reduces mortality among patients with sepsis and gram-negative bacteremia. Secondary endpoints, including resolution of organ failure, discharge from intensive care unit, and discharge from the hospital, support the beneficial effects of the antibody. The antibody is well tolerated with rare side effects, including hypotension and urticarial rash. No anti-HA-1A antibodies have been detected.
Smith
C R
CR
Centocor, Inc., Malvern, Pennsylvania.
Straube
R C
RC
Ziegler
E J
EJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016905:Gram-Negative Bacterial Infections / Q000628:therapy*; D006801:Humans; D007075:Immunoglobulin M / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007075:Immunoglobulin M; C068069:nebacumab